Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05678023 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study About Contrast Media

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment target: 70 to 120v4 Show 5 more changesShow less
    • Primary completion date: Sep 30, 2024 to Mar 30, 2025
    • Start date: Apr 1, 2023 to Sep 1, 2023
    • Study completion date: Apr 1, 2025 to Aug 1, 2025
    • Study description shortened, about 6 words
    • Collaborator revised
  2. Primary completion date: Mar 31, 2024 to Sep 30, 2024
    • Study completion date: Jul 31, 2024 to Apr 1, 2025
    v3
  3. Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Start date changed from estimate of Jan 1, 2023 to Apr 1, 2023
    • Study sites: 0 to 1
    • Primary completion date: Dec 31, 2023 to Mar 31, 2024
    • Study completion date: Dec 31, 2023 to Jul 31, 2024
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Patients hospitalized with adhesive small bowel obstruction (SBO) are randomized to 2 study groups at admission after signing an informed consent form. Water-soluble contrast media (CM) will be administered after 4 or after 24 hours of nasogastric- tube decompression.
Trial Details
NCT Number NCT05678023
Lead Sponsor University of Tartu
Collaborators: North Estonia Medical Centre
Conditions
(from sponsor)		 Small Bowel Obstruction
Enrollment 120 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov